、 Quinoline, 2-methyl-5-(trifluoromethyl)- 、 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 在
silica gel 、 ethyl acetate n-hexane 作用下,
以
四氯化碳 为溶剂,
以provided the title compound (103 mg, 37%) as a white solid的产率得到2-(bromomethyl)-5-(trifluoromethyl)quinoline
参考文献:
名称:
Substituted Heterocyclic Ethers and Their Use in CNS Disorders
[EN] SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS<br/>[FR] ETHERS HÉTÉROCYCLIQUES SUBSTITUÉS ET LEUR UTILISATION DANS DES TROUBLES DU SNC
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2009009633A1
公开(公告)日:2009-01-15
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
Compounds having the formula:
are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating diarrhea, hypertension, angina, platelet aggregation, cerebral spasm, premature labor, spontaneous abortion, dysmenorrhea, and migraine.